CWICX
Price
$80.79
Change
+$0.08 (+0.10%)
Updated
Jul 10 closing price
Net Assets
157.74B
RGLFX
Price
$31.31
Change
-$0.06 (-0.19%)
Updated
Jul 10 closing price
Net Assets
21.64B
Interact to see
Advertisement

CWICX vs RGLFX

CWICX vs RGLFX Comparison Chart in %
View a ticker or compare two or three
VS
CWICX vs. RGLFX commentary
Jul 13, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CWICX is a Buy and RGLFX is a StrongBuy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CWICX has more cash in the bank: 158B vs. RGLFX (21.6B). RGLFX pays higher dividends than CWICX: RGLFX (1.02) vs CWICX (0.66). CWICX was incepted earlier than RGLFX: CWICX (24 years) vs RGLFX (7 years). CWICX (1.52) is less costly to investors than RGLFX (0.51). CWICX is a more actively managed with annual turnover of: 44.00 vs. RGLFX (35.00). CWICX (250) and RGLFX (250) have matching initial minimum investment requirements. RGLFX annual gain was more profitable for investors over the last year : 18.88 vs. CWICX (14.11). RGLFX return over 5 years is better than : 55.34 vs. CWICX (30.57).
CWICXRGLFXCWICX / RGLFX
Total Expense Ratio1.520.51298%
Annual Report Gross Expense Ratio1.520.51298%
Fund Existence24 years7 years-
Gain YTD14.13910.363136%
Front LoadN/AN/A-
Min. Initial Investment250250100%
Min. Initial Investment IRAN/AN/A-
Net Assets158B21.6B731%
Annual Yield % from dividends0.661.0264%
Returns for 1 year14.1118.8875%
Returns for 3 years45.9059.3677%
Returns for 5 years30.5755.3455%
Returns for 10 years101.26N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GVEQX157.580.90
+0.57%
Government Street Equity
NEFSX45.550.20
+0.44%
Natixis US Equity Opportunities A
CSSZX26.780.09
+0.34%
Columbia Select Small Cap Value Inst
VEUSX110.720.11
+0.10%
Vanguard European Stock Admiral
FRSIX16.00-0.12
-0.74%
Franklin Small-Mid Cap Growth C